212 related articles for article (PubMed ID: 26916179)
1. Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.
Laforce R; Rosa-Neto P; Soucy JP; Rabinovici GD; Dubois B; Gauthier S
Can J Neurol Sci; 2016 Jul; 43(4):503-12. PubMed ID: 26916179
[TBL] [Abstract][Full Text] [Related]
2. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.
Johnson KA; Minoshima S; Bohnen NI; Donohoe KJ; Foster NL; Herscovitch P; Karlawish JH; Rowe CC; Carrillo MC; Hartley DM; Hedrick S; Pappas V; Thies WH
J Nucl Med; 2013 Mar; 54(3):476-90. PubMed ID: 23359661
[TBL] [Abstract][Full Text] [Related]
3. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.
Johnson KA; Minoshima S; Bohnen NI; Donohoe KJ; Foster NL; Herscovitch P; Karlawish JH; Rowe CC; Carrillo MC; Hartley DM; Hedrick S; Pappas V; Thies WH; ; ;
Alzheimers Dement; 2013 Jan; 9(1):e-1-16. PubMed ID: 23360977
[TBL] [Abstract][Full Text] [Related]
4. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
5. Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.
Rabinovici GD; Karlawish J; Knopman D; Snyder HM; Sperling R; Carrillo MC
Alzheimers Dement; 2016 Apr; 12(4):510-5. PubMed ID: 27103054
[TBL] [Abstract][Full Text] [Related]
6. Molecular imaging of dementia.
Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
[TBL] [Abstract][Full Text] [Related]
7. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.
Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL
Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942
[TBL] [Abstract][Full Text] [Related]
8. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
[TBL] [Abstract][Full Text] [Related]
9. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging.
Johnson KA; Minoshima S; Bohnen NI; Donohoe KJ; Foster NL; Herscovitch P; Karlawish JH; Rowe CC; Hedrick S; Pappas V; Carrillo MC; Hartley DM;
Alzheimers Dement; 2013 Jul; 9(4):e106-9. PubMed ID: 23809369
[TBL] [Abstract][Full Text] [Related]
10. Amyloid biomarkers in Alzheimer's disease.
Blennow K; Mattsson N; Schöll M; Hansson O; Zetterberg H
Trends Pharmacol Sci; 2015 May; 36(5):297-309. PubMed ID: 25840462
[TBL] [Abstract][Full Text] [Related]
11. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment.
Schmand B; Eikelenboom P; van Gool WA;
J Alzheimers Dis; 2012; 29(3):641-8. PubMed ID: 22297644
[TBL] [Abstract][Full Text] [Related]
12. Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice.
Guerra UP; Nobili FM; Padovani A; Perani D; Pupi A; Sorbi S; Trabucchi M
Neurol Sci; 2015 Jun; 36(6):1075-81. PubMed ID: 25616445
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
14. [Biomarkers for early diagnosis of Alzheimer's disease].
Frederiksen KS; Hasselbalch S; Law I; Højgaard L; Waldemar G
Ugeskr Laeger; 2015 Jun; 177(24):. PubMed ID: 26058526
[TBL] [Abstract][Full Text] [Related]
15. Will PET amyloid imaging lead to overdiagnosis of Alzheimer dementia?
Dubroff JG; Nasrallah IM
Acad Radiol; 2015 Aug; 22(8):988-94. PubMed ID: 26100192
[TBL] [Abstract][Full Text] [Related]
16. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education.
Johnson KA; Minoshima S; Bohnen NI; Donohoe KJ; Foster NL; Herscovitch P; Karlawish JH; Rowe CC; Hedrick S; Pappas V; Carrillo MC; Hartley DM
J Nucl Med; 2013 Jul; 54(7):1011-3. PubMed ID: 23753186
[TBL] [Abstract][Full Text] [Related]
17. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
[TBL] [Abstract][Full Text] [Related]
18. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
19. The interest of amyloid PET imaging in the diagnosis of Alzheimer's disease.
Vandenberghe R; Adamczuk K; Van Laere K
Curr Opin Neurol; 2013 Dec; 26(6):646-55. PubMed ID: 24145484
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
Shea YF; Ha J; Chu LW
Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
